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Recently Christian Hudert and colleagues 
from the Charité in Berlin published a study 
about genetic determinants in pediatric non-
alcoholic liver disease (Hudert et al., 2018). 
Non-alcoholic fatty liver disease (NAFLD), 
the most frequent chronic liver disease in chil-
dren, is known to be strongly influenced by 
genetic factors (Nobili et al., 2016; Schwim-
mer et al., 2006; Makkonen et al., 2009; An-
stee et al., 2016). However, genetic determi-
nants of a portal/zone-1 pattern of steatosis in 
children are not yet known. This would be im-
portant, because a portal/zone-1 pattern of 
steatosis leads to an increased risk of disease 
progression to fibrosis (Africa et al., 2018; 
Mann et al., 2016). To address this question, 
the authors established the Berlin adolescence 
NAFLD cohort (BaNA) and studied a set of 
single nucleotide polymorphisms. Interest-
ingly, a variant of the retinyl-palmitate lipase 
PNPLA3 (rs738409) was associated with a 
periportal pattern of steatosis and also with an 
increased risk of progression to fibrosis 
(Hudert et al., 2018). Therefore, obese chil-
dren with the PNPLA3 variant may be candi-
dates for a more intensive clinical follow-up 
and intervention. 
Due to the current increase in the inci-
dence of liver diseases a better understanding 
of their pathophysiology is of major im-
portance (Jansen et al., 2017; Vartak et al., 
2016; Hammad et al., 2014; Hassan, 2016; 
Stöber, 2016; Bolt, 2017; Ekhlasi et al., 
2017). For this purpose systems modeling as 
well as the analysis of expression patterns in 
relation to a phenotype represent frequently 
applied tools (Godoy et al., 2016; Crespo 
Yanguas et al., 2016; Jain et al., 2016; Saleem 
et al., 2016; Schenk et al., 2017; Thiel et al., 
2015). The newly established BaNA cohort of 
adolescent NAFLD with its careful phenotyp-
ing and availability of proteome data is an im-
portant milestone for a better understanding 
of disease progression in steatosis.  
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